CYCC
NSCCyclacel Pharmaceuticals Inc.
Healthcare•Biotechnology
Watchlist:
Last updated: Thursday 3rd July 2025
0.25
-0.09 (-26.29%)
Prev Close:0.3363
Open:0.29
Bid:0.2493
Ask:0.2498
52 Week Range
0.2339.84
Volume:1,481,818
Mkt Cap:7 M
19
MarketXLS Rank ®
Sell
Price Target
$0.29
+17.0%
Metrics
Valuation
525.47
0.00
Range data not available
Returns
-32.18%
-84.88%
-93.26%
-99.07%
-99.91%
-99.98%
-95.92%
Growth
EPS
QoQ
N/A
YoY
N/A
Revenue
QoQ
N/A
YoY
N/A
Free Cash Flow
QoQ
N/A
YoY
N/A
Peers
Risk
Risk Metrics
Financial Scores
0.00
0.00
Dividends
Dividend Metrics
Dividend Yields
Dividend Dates
Analyst Estimates
EPS Estimates
Target Prices
Growth Estimates
Financial Health
Cash Metrics
Liquidity Ratios
5.60
5.20
Debt Metrics
Other Metrics
Financial Scores
Technicals
Technical Oscillators
Moving Averages
Volatility Metrics
Profitability
Return Ratios
Margin Ratios
-55578.6
100.0
Financial Scores
Financials
Financial Statements
CYCC - Income Statement (Annual)
Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
---|---|---|---|---|---|---|---|---|---|---|
Accretion On Preferred Stock | 135000.0 | |||||||||
Accrued Preferred Stock Dividends | 201000.0 | 201000.0 | 201000.0 | 4 M | 201000.0 | 201000.0 | 7 M | 200000.0 | 201000.0 | |
Basic EPS From Continuing Operations | -2.09 | -456.0 | -513.6 | -820.8 | -9360.0 | -16800.0 | ||||
Basic EPS Total | -2.09 | -456.0 | -513.6 | -820.8 | -9360.0 | -16800.0 | ||||
Basic Weighted Shares Outstanding | 5 M | 46898.0 | 37192.0 | 15139.0 | 3400.0 | 2519.0 | 1589.0 | 713.0 | 565.0 | |
Depreciation | 20000.0 | -20000.0 | -29000.0 | -32 M | ||||||
Depreciation And Amortization | 20000.0 | -20000.0 | -29000.0 | -32 M | ||||||
Diluted EPS Total | -2.09 | -456.0 | -513.6 | -820.8 | -2352.0 | -2976.0 | -9360.0 | -16800.0 | ||
Diluted Normalized Net Income/share | -2.09 | -456.0 | -513.6 | |||||||
Diluted Weighted Shares Outstanding | 5 M | 46898.0 | 37192.0 | 3329.0 | 2898.0 | 1589.0 | 713.0 | |||
General And Administrative Expense | 5 M | 7 M | 7 M | 7 M | 6 M | -300000.0 | -400000.0 | 5 M | 6 M | |
Gross Operating Profit | 43000.0 | 420000.0 | 843000.0 | 2 M | ||||||
Income Before Tax | -12 M | -26 M | -26 M | -23 M | -10 M | -9 M | -9 M | -8 M | -14 M | -16 M |
Income Taxes | -782000.0 | -3 M | -5 M | -4 M | -1 M | -1 M | -1 M | -4 M | -2 M | -2 M |
Interest Income | 12000.0 | 266000.0 | 210000.0 | 16000.0 | 42000.0 | 224000.0 | 331000.0 | 118000.0 | 37000.0 | -42000.0 |
Misc Other Special Charges | 52000.0 | 50000.0 | 1 M | 144000.0 | 891000.0 | 231000.0 | 832000.0 | 949000.0 | 66000.0 | 94000.0 |
Net Income From Total Operations | -11 M | -23 M | -21 M | -18 M | -8 M | -8 M | -7 M | -8 M | -14 M | -14 M |
Net Income Common Stockholders | -11 M | -23 M | -21 M | -19 M | -12 M | -8 M | -7 M | -16 M | -14 M | -15 M |
Net Income Continuous Operations | -11 M | -23 M | -21 M | -19 M | -8 M | -8 M | -7 M | -8 M | -14 M | -14 M |
Net Non Operating Interest Income Expense | 12000.0 | 266000.0 | 210000.0 | 16000.0 | 42000.0 | 224000.0 | 331000.0 | 118000.0 | 37000.0 | -42000.0 |
Normalized Income | -13 M | -27 M | ||||||||
Operating Income | -12 M | -25 M | -28 M | -23 M | -11 M | -10 M | -10 M | -9 M | -14 M | -16 M |
Operating Income Before Depreciation (EBITDA) | -12 M | -26 M | -28 M | -22 M | -11 M | -9 M | -9 M | -8 M | -14 M | -16 M |
Operating Expense | 12 M | 26 M | 28 M | 23 M | 11 M | 10 M | 10 M | 9 M | 15 M | 18 M |
Other Income Net | -52000.0 | -50000.0 | 2 M | -144000.0 | -891000.0 | -231000.0 | -832000.0 | -949000.0 | -66000.0 | -94000.0 |
Other Gand A | 5 M | 7 M | 7 M | 7 M | 6 M | -300000.0 | -400000.0 | 5 M | 6 M | |
Other Operating Expenses | 12 M | 26 M | 62528.0 | 200000.0 | 400000.0 | |||||
Otherunder Preferred Stock Dividend | 201000.0 | 201000.0 | 201000.0 | 4 M | 201000.0 | 201000.0 | 7 M | 200000.0 | 201000.0 | |
Preferred Stock Dividends | 201000.0 | 201000.0 | 201000.0 | 4 M | 201000.0 | 201000.0 | 7 M | 200000.0 | 201000.0 | |
Rent And Landing Fees | -400000.0 | -500000.0 | ||||||||
Research & Development Expense | 7 M | 19 M | 20 M | 15 M | 5 M | 5 M | 4 M | 4 M | 9 M | 12 M |
Research Expense | 7 M | 19 M | 20 M | 15 M | 5 M | 5 M | 4 M | 4 M | 9 M | 12 M |
Salaries And Wages | 592000.0 | 1 M | -466000.0 | -331000.0 | ||||||
Selling Gen & Administrative Expense | 5 M | 7 M | 7 M | 7 M | 6 M | 5 M | 5 M | 5 M | 6 M | 6 M |
Selling And Marketing Expense | 5 M | 5 M | 6 M | |||||||
Selling Expense | 5 M | 5 M | 6 M | |||||||
Total Income Available For Interest Expense (EBIT) | -12 M | -26 M | -28 M | -22 M | -11 M | -9 M | -9 M | -8 M | -14 M | -16 M |
Total Common Shares Outstanding | 82391.0 | 52246.0 | 41638.0 | 29598.0 | 3583.0 | 3583.0 | 2499.0 | 890.0 | 617.0 | |
Total Net Income | -11 M | -23 M | -21 M | -18 M | -8 M | -8 M | -7 M | -8 M | -14 M | -14 M |
Total Ordinary Shares | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M |
Total Revenues | 43000.0 | 420000.0 | 150000.0 | 843000.0 | 2 M | |||||
Total Expenses | 12 M | 26 M | 28 M | 23 M | 11 M | 10 M | 10 M | 9 M | 15 M | 18 M |
Total Revenue | 43000.0 | 420000.0 | 150000.0 | 843000.0 | 2 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.